Stocks · News reference
Wedbush analyst Robert Driscoll maintains Aprea Therapeutics (NASDAQ:APRE) with a Outperform and lowers the price target from $6 to $3.
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-08-12 AccNo: 0001104659-26-094542 Size: 6 MB Item 2.02: Results of Operations and Financial Condition Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read original at edgarAprea Therapeutics (NASDAQ:APRE) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.23) by 69.57 percent. This is a 86.79 percent increase over losses of $(0.53) per share
Read original at benzinga